Compare DexCom, Inc. (DXCM) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: DexCom, Inc. is far larger — about 56.9× Direxion Daily FTSE China Bull 3x Shares's market cap, and DexCom, Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| DXCM | YINN | |
|---|---|---|
Market Cap | $31.86B | $560.32M |
Volume | 3,607,070 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $52.69 |
52-Week Low | $54.84 | $21.45 |
Typical Hold Time | 62 Days | 25 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
YINN trades at $23.63, up 0.3% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks key financial ratio disclosures, limiting fundamental clarity. Recent news highlights China's economic policies and export controls, which may influence the fund's underlying holdings.
The outlook is cautious due to bearish technicals and exposure to Chinese market volatility. Opportunities exist if Chinese equities rebound, but risks include regulatory tightening and economic slowdowns. Investors should weigh technical weakness against potential regional catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
